NKGEN BIOTECH INC (NKGN) Stock Price & Overview
NASDAQ:NKGN • US65488A1016
The current stock price of NKGN is 0.1913 USD. Today NKGN is down by -62.91%. In the past month the price decreased by -59.77%. In the past year, price decreased by -91.22%.
NKGN Key Statistics
- Market Cap
- 8.599M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -4.71
- Dividend Yield
- N/A
NKGN Stock Performance
NKGN Stock Chart
NKGN Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to NKGN. When comparing the yearly performance of all stocks, NKGN is a bad performer in the overall market: 98.57% of all stocks are doing better.
NKGN Earnings
NKGN Forecast & Estimates
NKGN Groups
Sector & Classification
NKGN Financial Highlights
Over the last trailing twelve months NKGN reported a non-GAAP Earnings per Share(EPS) of -4.71. The EPS decreased by -50.84% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -564.01% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
NKGN Ownership
NKGN Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 16.26 | 413.319B | ||
| AMGN | AMGEN INC | 16.83 | 203.007B | ||
| GILD | GILEAD SCIENCES INC | 16.62 | 183.41B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.44 | 120.332B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.95 | 81.051B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 48.86 | 42.097B | ||
| INSM | INSMED INC | N/A | 31.351B | ||
| NTRA | NATERA INC | N/A | 29.344B | ||
| BIIB | BIOGEN INC | 12.48 | 27.007B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.41 | 21.856B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.914B | ||
| EXAS | EXACT SCIENCES CORP | 309.36 | 19.724B | ||
| MRNA | MODERNA INC | N/A | 19.468B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About NKGN
Company Profile
NKGen Biotech, Inc. is a clinical-stage biotechnology company, which focuses on the development and commercialization of innovative autologous, allogeneic, and CAR-NK cell therapies utilizing a proprietary SNK platform. The company is headquartered in Santa Ana, California and currently employs 63 full-time employees. The company went IPO on 2021-05-21. The firm is focused on the development and commercialization of autologous, allogeneic, and CAR-NK natural killer cell therapeutics. Its product candidates are based on a manufacturing and cryopreservation process, which produces SuperNK (SNK) cells. SNK cells can be produced in large quantities and cryopreserved, while maintaining high levels of cytotoxicity and activating receptor expression after thawing and reconstitution. The company is developing SNK01, an autologous natural killer (NK) cell therapy, for the treatment of neurodegenerative diseases, including Alzheimer’s disease (AD) and Parkinson’s disease (PD). Its autologous NK cell therapy candidate has clinical trials in several therapeutic areas, including oncology and neurodegeneration. SNK02 is its allogeneic NK cell product candidate. The company is conducting clinical trials with its SNK cell therapy in patients with neurodegenerative disease (SNK01) and cancer (SNK02).
Company Info
NKGEN BIOTECH INC
3001 Daimler St,
Santa Ana CALIFORNIA US
Employees: 63
Phone: 19493966830
NKGEN BIOTECH INC / NKGN FAQ
What does NKGN do?
NKGen Biotech, Inc. is a clinical-stage biotechnology company, which focuses on the development and commercialization of innovative autologous, allogeneic, and CAR-NK cell therapies utilizing a proprietary SNK platform. The company is headquartered in Santa Ana, California and currently employs 63 full-time employees. The company went IPO on 2021-05-21. The firm is focused on the development and commercialization of autologous, allogeneic, and CAR-NK natural killer cell therapeutics. Its product candidates are based on a manufacturing and cryopreservation process, which produces SuperNK (SNK) cells. SNK cells can be produced in large quantities and cryopreserved, while maintaining high levels of cytotoxicity and activating receptor expression after thawing and reconstitution. The company is developing SNK01, an autologous natural killer (NK) cell therapy, for the treatment of neurodegenerative diseases, including Alzheimer’s disease (AD) and Parkinson’s disease (PD). Its autologous NK cell therapy candidate has clinical trials in several therapeutic areas, including oncology and neurodegeneration. SNK02 is its allogeneic NK cell product candidate. The company is conducting clinical trials with its SNK cell therapy in patients with neurodegenerative disease (SNK01) and cancer (SNK02).
What is the current price of NKGN stock?
The current stock price of NKGN is 0.1913 USD. The price decreased by -62.91% in the last trading session.
Does NKGN stock pay dividends?
NKGN does not pay a dividend.
How is the ChartMill rating for NKGEN BIOTECH INC?
NKGN has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 0 out of 10.